Founded in 2021, A28 Therapeutics is a privately-held, clinical-stage biopharmaceutical company focused on the development of its targeted lytic peptide platform for the treatment of multiple cancer types.

Our lead proprietary agent, AT-101, has demonstrated the potential to deliver safe and effective cancer treatment alone and in combination with multiple classes of cancer medications including immuno-oncology medications and chemotherapy. Our lead indications are metastatic ovarian cancer with liver metastases and hepatocellular carcinoma, and we are in late-stage development in both indications. In addition, A28 is preparing to study the benefits of AT-101 in combination with immuno-oncology therapeutics in various solid tumors with liver metastases.

Our goal at A28 is to deliver innovative, game-changing cancer care to patients worldwide.

The A28 Leadership Team

Experience, expertise, and relevant domain knowledge to create significant value in the A28 targeted lytic peptide platform.

Stanley Lewis

Stanley Lewis M.D., M.P.H.

Founder and CEO

  • 20+ years as biotechnology executive
  • Former CMO of TaiMed Biologics (public), Ansun Biopharma (private) and Director of Drug Development at Tanox (sold to Genentech)
  • Developed TROGARZO® from Phase 1 to BLA

Read Bio

Stanley Lewis

Stanley Lewis M.D., M.P.H.

Founder and CEO

Dr. Lewis is a proven leader in life sciences, with 25 years of experience in clinical research, drug development, patient care and teaching. He founded A28 Therapeutics in 2021 and serves as Chief Executive Officer.

Previously, Dr. Lewis served as Chief Medical Officer and in various clinical development roles, most recently as CMO of Ansun Biopharma where he successfully led the company’s late-stage clinical trials of therapies for parainfluenza, influenza, and COVID-19, anchored its fundraising team on the way to securing $100M in Series B financing, and provided strategic leadership on the company’s in-licensing efforts.

Prior to joining Ansun, Dr. Lewis was CMO at TaiMed Biologics where he led the company to US FDA approval of TROGARZO™, the first long-acting agent and the first monoclonal antibody treatment for multi-drug resistant HIV disease. He was instrumental in securing additional regulatory designations and grant funding, as well as manufacturing and commercial licensing for TaiMed development programs. Dr. Lewis serves on multiple scientific and medical advisory boards for both for-profit and non-profit organizations focused on improving healthcare, clinical research, and education.

Dr. Lewis is a graduate of the University of Texas McGovern Medical School where he completed his internship, residency, and fellowship in Internal Medicine. He also earned a Master’s in Public Health while serving as Assistant Professor of Medicine in the Department of Internal Medicine. Dr. Lewis completed his undergraduate education at the University of Texas at Austin. Dr. Lewis has published dozens of peer-reviewed articles, holds multiple patents and patents pending, and has been a principal or co-investigator on numerous Phase 1-4 clinical trials.

Tom Kottler

Tom Kottler

President, COO and Co-founder

  • 20+ years as healthcare entrepreneur
  • Co-founded/on initial management team of 6 healthcare companies
  • Managed start-up, growth and exit of multiple entities

Read Bio

Tom Kottler

Tom Kottler

President, COO and Co-founder

Mr. Kottler co-founded A28 Therapeutics in 2021 and serves as President and Chief Operating Officer. He is a seasoned entrepreneur with more than 20 years of experience founding, managing and leading innovative healthcare companies.

Mr. Kottler has served as CEO of multiple healthcare startups across all stages of development, including company founding and initial strategic development, regulatory planning, restructuring, commercialization and successful exit, and he has a proven record of raising financing and delivering revenue growth. Most recently, Mr. Kottler was CEO and co-founder of HealthPrize Technologies. He also currently serves as Executive Chairman of digital health company Essence Patient Solutions.

Mr. Kottler began his career in law, having been a corporate litigator for almost 10 years. He holds a JD from The George Washington University National Law Center in Washington, DC, and a Bachelor of Arts from Middlebury College.

Carola Leuschner

Carola Leuschner, Ph.D.

VP of Research & Development

  • Ph.D. in biochemistry from University of Hanover, Germany
  • VP of Research and Development, Esperance Pharmaceuticals
  • Associate Professor, Pennington Research Center

Read Bio

Carola Leuschner

Carola Leuschner, Ph.D.

VP of Research & Development

Dr. Leuschner is Vice President, Research & Development for A28 Therapeutics. A clinical researcher and biotechnology innovator, she has more than 20 years of experience designing, testing and developing anticancer drugs.

Dr. Leuschner previously served as Vice President of R&D for Esperance Pharmaceuticals, where she led the discovery and development of the company’s lead compound, now known as AT-101, from pre-clinical to clinical stage prior to the compound’s acquisition by A28 Therapeutics in 2021. She is the co-inventor of the therapeutic platform, for which she holds 11 issued and 3 pending patents in the US and several other countries to date.

Previously, Dr. Leuschner served as Associate Professor at the Pennington Biomedical Research Center, Baton Rouge, Louisiana, where she advanced research in the field of membrane disrupting peptide conjugates for cancer treatment, and nanoparticles for imaging and treatment. She is the author of more than 40 peer-reviewed publications, more than 50 peer-reviewed abstracts, and various book chapters and review articles, and she has extensive experience securing grant funding for clinical research and seed financing to drive advances in the treatment of cancer.

Dr. Leuschner is an active member of the American Association of Cancer Research (AACR), the American Cancer Society (ACS) and the Society for Immunotherapy of Cancer (SITC). She also serves as board member for an organization developing a CBD-based treatment for cancer, as well as an organization developing treatments for pain and various skin conditions. Dr. Leuschner holds a B.S., M.S. in Chemistry and Biology and a Ph.D. in Biochemistry from the University of Hanover, Germany.

Our Advisors

Anil Sood

Dr. Anil Sood

Medical Advisor

Anil Sood

Dr. Anil Sood

Medical Advisor

Rob Coleman

Dr. Rob Coleman

Medical Advisor

Rob Coleman

Dr. Rob Coleman

Medical Advisor

Dr. Daniel Von Hoff

Dr. Daniel Von Hoff

Medical Advisor

Dr. Daniel Von Hoff

Dr. Daniel Von Hoff

Medical Advisor

Dr. Ahmed Kaseb

Dr. Ahmed Kaseb

Medical Advisor

Dr. Ahmed Kaseb

Dr. Ahmed Kaseb

Medical Advisor

Dieter Weinand

Dieter Weinand

Business Advisor

Dieter Weinand

Dieter Weinand

Business Advisor

Darius Naigamwalla

Darius Naigamwalla

Business Advisor

Darius Naigamwalla

Darius Naigamwalla

Business Advisor

Amit Munshi

Amit Munshi

Business Advisor

Amit Munshi

Amit Munshi

Business Advisor

Ted Love

Ted Love

Business Advisor

Ted Love

Ted Love

Business Advisor

Michael Wood

Michael Wood

Business Advisor

Michael Wood

Michael Wood

Business Advisor

Rhonda Wallen

Rhonda Wallen

Business Advisor

Rhonda Wallen

Rhonda Wallen

Business Advisor

Melody Smith

Melody Smith

Medical Advisor

Melody Smith

Melody Smith

Medical Advisor

Learn Why Targeted Lytic Peptides Are a Promising Treatment for Multiple Cancer Types

Interested in learning more about the A28 targeted lytic peptide platform? We would be pleased to have an opportunity to share our compelling story, platform, pipeline, and data with you.

Contact Us